Your shopping cart is currently empty

STAT3-IN-12, a potent STAT3 signaling inhibitor, suppresses IL-6-induced JAK/STAT3 pathway activation. This compound inhibits cancer cell proliferation and migration while inducing apoptosis and cell cycle arrest, making it suitable for hepatocellular carcinoma (HCC) and esophageal cancer research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $52 | - | In Stock | |
| 5 mg | $123 | - | In Stock | |
| 10 mg | $189 | - | In Stock | |
| 25 mg | $396 | - | In Stock | |
| 50 mg | $569 | - | In Stock | |
| 100 mg | $745 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $135 | - | In Stock |
| Description | STAT3-IN-12, a potent STAT3 signaling inhibitor, suppresses IL-6-induced JAK/STAT3 pathway activation. This compound inhibits cancer cell proliferation and migration while inducing apoptosis and cell cycle arrest, making it suitable for hepatocellular carcinoma (HCC) and esophageal cancer research. |
| Targets&IC50 | HepG2 cells:4.32 μM, EC109 cells:3.63 μM |
| In vitro | Methods: HepG2 and EC109 cells were treated with STAT3-IN-12 (0, 1.25, 2.5, 5, 10 μM, 16-72 hours) and subjected to cell viability assays, cell migration assays, and Western blotting. Results: STAT3-IN-12 inhibited the growth of HepG2 and EC109 cells with IC50 values of 4.32 μM and 3.63 μM, respectively. It selectively inhibited STAT3 tyrosine 705 phosphorylation after 16 hours of treatment. [1] |
| In vivo | Methods: STAT3-IN-12 (20, 40 mg/kg intraperitoneal injection, daily for 24 days) was used to treat HepG2 cell xenograft tumor model mice to study its effect on tumor growth in mice. Results: STAT3-IN-12 was able to inhibit tumor growth in mice without affecting the body weight of the mice. [1] |
| Molecular Weight | 454.56 |
| Formula | C28H30N4O2 |
| Cas No. | 2980758-31-2 |
| Smiles | N=1C=2C=C3N=C(C=4C=CC=C(OC)C4)N(C3=CC2N(C1C=5C=CC=C(OC)C5)CCC)CCC |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (175.99 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.